DSM Capital Partners LLC Increases Holdings in Stryker Corporation $SYK

DSM Capital Partners LLC lifted its stake in shares of Stryker Corporation (NYSE:SYK) by 53.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 28,927 shares of the medical technology company’s stock after purchasing an additional 10,021 shares during the quarter. DSM Capital Partners LLC’s holdings in Stryker were worth $9,505,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. Sankala Group LLC purchased a new position in Stryker during the 4th quarter valued at about $26,000. Godfrey Financial Associates Inc. bought a new stake in shares of Stryker during the fourth quarter valued at about $26,000. United Financial Planning Group LLC purchased a new stake in shares of Stryker in the third quarter worth about $27,000. Atlas Capital Advisors Inc. bought a new position in shares of Stryker in the fourth quarter valued at approximately $27,000. Finally, DJE Kapital AG bought a new position in shares of Stryker in the fourth quarter valued at approximately $28,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of analyst reports. JPMorgan Chase & Co. decreased their target price on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a report on Friday, May 1st. Weiss Ratings lowered shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. BMO Capital Markets started coverage on shares of Stryker in a report on Wednesday. They issued an “outperform” rating and a $369.00 price target on the stock. Finally, Leerink Partners lowered their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $393.91.

Insider Buying and Selling

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 323,264 shares of company stock worth $100,659,489. Corporate insiders own 4.60% of the company’s stock.

Stryker Stock Down 0.8%

SYK stock opened at $327.17 on Thursday. The company’s 50 day moving average is $309.71 and its 200 day moving average is $338.22. The stock has a market cap of $125.42 billion, a price-to-earnings ratio of 37.87, a price-to-earnings-growth ratio of 2.11 and a beta of 0.77. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter in the previous year, the firm earned $2.84 earnings per share. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Sell-side analysts predict that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is currently 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.